TP53 and astrocytoma (excluding glioblastoma): Early GEMMS for pediatric gliomas leveraged Nf1 and Trp53 mutations by crossbreeding individual knockout strains to produce the desired Nf1 and Trp53 dual-combination knockout, producing tumor-bearing mice that had a range of astrocytomas of all stages with representative histopathological features [53,71].